Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque
Alastair J. Moss, Marc R. Dweck, Mhairi K. Doris, Jack P.M. Andrews, Rong Bing, Rachael O. Forsythe, Timothy R. Cartlidge, Tania A. Pawade, Marwa Daghem, Jennifer B. Raftis, Michelle C. Williams, Edwin J.R. van Beek, Laura Forsyth, Steff C. Lewis, Robert J. Lee, Anoop S.V. Shah, Nicholas L. Mills, David E. Newby and Philip D. Adamson
Using Coronary 18F-Fluoride to Identify Patients Who May Benefit From Intensified Dual Antiplatelet Therapy
Coronary 18F-fluoride positron emission tomography was used to identify high-risk coronary plaque in patients with stable multivessel coronary artery disease. Randomization to intensified dual antiplatelet therapy with ticagrelor did not reduce plasma high-sensitivity cardiac troponin I concentrations at 30 days in patients with high-risk plaque.